keyword
MENU ▼
Read by QxMD icon Read
search

Pharmaceuticals

keyword
https://www.readbyqxmd.com/read/28945022/-progress-of-gene-editing-technologies-and-prospect-in-traditional-chinese-medicine
#1
REVIEW
Yan-Yan Ma, Jing-Zhe Li, Er-Ning Gao, Dan Qian, Ju-Ying Zhong, Chang-Zhen Liu
Gene editing is a kind of technologies that makes precise modification to the genome. It can be used to knock out/in and replace the specific DNA fragment, and make accurate gene editing on the genome level. The essence of the technique is the DNA sequence change with use of non homologous end link repair and homologous recombination repair, combined with specific DNA target recognition and endonuclease.This technology has wide range of development prospects and high application value in terms of scientific research, agriculture, medical treatment and other fields...
January 2017: Zhongguo Zhong Yao za Zhi, Zhongguo Zhongyao Zazhi, China Journal of Chinese Materia Medica
https://www.readbyqxmd.com/read/28945021/-progress-of-new-antidepressant-drugs-development
#2
REVIEW
Xiao Zhang, Jun-Sheng Tian, Huan Liu, Xue-Mei Qin
Depression becomes more and more serious and has been greatly do harm to human's physical and mental health. WHO predicts that depression will become the second leading cause of abnormal death and disability by 2020. There is still the drug treatment as the first-line antidepressive therapy, but the effect of listed antidepressant drugs is not ideal. Therefore, discovery of new antidepressant drug of sunique, higher curative effect, less adverse reaction is the pursuit of pharmaceutical. The traditional Chinese medicine (TCM) of anti-depression and natural antidepressant in currently listed, drug development and drug discovery phase are summarized in this paper, aiming to provide reference for new antidepressant drug research...
January 2017: Zhongguo Zhong Yao za Zhi, Zhongguo Zhongyao Zazhi, China Journal of Chinese Materia Medica
https://www.readbyqxmd.com/read/28945018/-expert-consensus-on-the-design-and-implementation-of-clinical-safety-centralized-monitoring-study-of-chinese-medical-injection
#3
Jun-Hua Zhang, Jing-Tian Ren, Jing-Qing Hu, Yan-Ming Xie, Hai-Bo Song, Ming-Jun Zhu, Rui Gao, Zhong Wang, Wen-Ke Zheng, Xue-Lin Li, Meng Jiang, Yu-Hong Huang, Fang Lu, Li-Yun He, Wei-Xiong Lian, Zhong-Qi Yang, Wei-An Yuan, Si-Yuan Hu, Bao-He Wang, Wei-Liang Wang, De-Quan Ren, Bo-Li Zhang
Along with the increase of clinical application, the safety of traditional Chinese medicine gained more and more attentions. In particular, the safety evaluation of Chinese medical injections has become a mandatory task should be completed by pharmaceutical companies under the supervision of China Food and Drug Administration(CFDA). Due to the weak foundation of previous studies, the safety issues of Chinese medical injections have not been fully understood, and lack of scientific and rational risk management programs...
January 2017: Zhongguo Zhong Yao za Zhi, Zhongguo Zhongyao Zazhi, China Journal of Chinese Materia Medica
https://www.readbyqxmd.com/read/28945017/-a-strategy-of-constructing-the-technological-system-for-quality-control-of-chinese-medicine-based-on-process-control-and-management
#4
Yi-Yu Cheng, Zhong-Zhi Qian, Bo-Li Zhang
The current situation, bottleneck problems and severe challenges in quality control technology of Chinese Medicine (CM) are briefly described. It is presented to change the phenomenon related to the post-test as the main means and contempt for process control in drug regulation, reverse the situation of neglecting the development of process control and management technology for pharmaceutical manufacture and reconstruct the technological system for quality control of CM products. The regulation and technology system based on process control and management for controlling CM quality should be established to solve weighty realistic problems of CM industry from the root causes, including backwardness of quality control technology, weakness of quality risk control measures, poor reputation of product quality and so on...
January 2017: Zhongguo Zhong Yao za Zhi, Zhongguo Zhongyao Zazhi, China Journal of Chinese Materia Medica
https://www.readbyqxmd.com/read/28944734/outcomes-based-contracting-experience-research-findings-from-u-s-and-european-stakeholders
#5
Tara Nazareth, John J Ko, Rahul Sasane, Christian Frois, Stephen Carpenter, Sebastian Demean, Ashok Vegesna, Eric Wu, Robert P Navarro
BACKGROUND: Outcomes-based contracts (OBCs), a type of risk-sharing arrangement (RSA), have emerged as a promising avenue for payers to engage with pharmaceutical manufacturers to share risk and improve patient access to medicines via evaluation of real-world outcomes. OBJECTIVE: To assess the level of recent OBC activity and stakeholder perceptions of these arrangements, as well as the outlook for future OBC activity from a payer and manufacturer perspective in the United States and EU-5 (France, Germany, Italy, Spain, and the United Kingdom)...
October 2017: Journal of Managed Care & Specialty Pharmacy
https://www.readbyqxmd.com/read/28944733/performance-based-risk-sharing-arrangements-for-pharmaceutical-products-in-the-united-states-a-systematic-review
#6
Justin S Yu, Lauren Chin, Jennifer Oh, Jorge Farias
BACKGROUND: Value for money is a growing necessity in today's U.S. health care system in which drug spending is expected to increase by an average rate of 6.7% yearly through 2025. In response to uncertainty about real-world clinical and economic outcomes for many drugs, health insurers and pharmacy benefit managers (PBMs) have implemented various contracts and arrangements with drug manufacturers that can collectively be described as performance-based risk-sharing arrangements (PBRSAs)...
October 2017: Journal of Managed Care & Specialty Pharmacy
https://www.readbyqxmd.com/read/28944732/patient-centered-drug-approval-the-role-of-patient-advocacy-in-the-drug-approval-process
#7
T Joseph Mattingly, Linda Simoni-Wastila
Recent approval of eteplirsen for Duchenne muscular dystrophy (DMD), a rare disease with few treatment alternatives, has reignited the debate over the U.S. drug approval process. The evolution of legal and regulatory restrictions to the marketing and sale of pharmaceuticals has spanned more than a century, and throughout this history, patient advocacy has played a significant role. Scientific evidence from clinical trials serves as the foundation for drug approval, but the patient voice has become increasingly influential...
October 2017: Journal of Managed Care & Specialty Pharmacy
https://www.readbyqxmd.com/read/28944730/optimization-of-medication-use-at-accountable-care-organizations
#8
Chrisanne Wilks, Erik Krisle, Kimberly Westrich, Kristina Lunner, David Muhlestein, Robert Dubois
BACKGROUND: Optimized medication use involves the effective use of medications for better outcomes, improved patient experience, and lower costs. Few studies systematically gather data on the actions accountable care organizations (ACOs) have taken to optimize medication use. OBJECTIVES: To (a) assess how ACOs optimize medication use; (b) establish an association between efforts to optimize medication use and achievement on financial and quality metrics; (c) identify organizational factors that correlate with optimized medication use; and (d) identify barriers to optimized medication use...
October 2017: Journal of Managed Care & Specialty Pharmacy
https://www.readbyqxmd.com/read/28944729/using-performance-based-risk-sharing-arrangements-to-address-uncertainty-in-indication-based-pricing
#9
Kai Yeung, Meng Li, Josh J Carlson
BACKGROUND: The rise in pharmaceutical expenditures in recent years has increased health care payer interest in ensuring good value for the money. Indication-based pricing (IBP) sets separate, indication-specific prices paid to the manufacturer according to the expected efficacy of a drug in each of its indications. IBP allows payers to consistently pay for value across indications. While promising, a limitation of IBP as originally conceived is that efficacy estimates are typically based on clinical trial data, which may differ from real-world effectiveness...
October 2017: Journal of Managed Care & Specialty Pharmacy
https://www.readbyqxmd.com/read/28944728/performance-based-risk-sharing-arrangements-u-s-payer-experience
#10
Joseph A Goble, Brian Ung, Sascha van Boemmel-Wegmann, Robert P Navarro, Andrew Parece
BACKGROUND: As a result of global concern about rising drug costs, many U.S. payers and European agencies such as the National Health Service have partnered with pharmaceutical companies in performance-based risk-sharing arrangements (PBRSAs) by which manufacturers share financial risk with health care purchasing entities and authorities. However, PBRSAs present many administrative and legal challenges that have minimized successful contract experiences in the United States. OBJECTIVE: To (a) identify drug and disease characteristics and contract components that contribute to successful PBRSA experiences and the primary barriers to PBRSA execution and (b) explore solutions to facilitate contract negotiation and execution...
October 2017: Journal of Managed Care & Specialty Pharmacy
https://www.readbyqxmd.com/read/28944726/paying-for-cures-how-can-we-afford-it-managed-care-pharmacy-stakeholder-perceptions-of-policy-options-to-address-affordability-of-prescription-drugs
#11
Kai Yeung, Kangho Suh, Anirban Basu, Louis P Garrison, Aasthaa Bansal, Josh J Carlson
BACKGROUND: High-priced medications with curative potential, such as the newer hepatitis C therapies, have contributed to the recent growth in pharmaceutical expenditure. Despite the obvious benefits, health care decision makers are just beginning to grapple with questions of how to value and pay for curative therapies that may feature large upfront cost, followed by health benefits that are reaped over a patient's lifespan. Alternative policy options have been proposed to promote high value and financially sustainable use of these therapies...
October 2017: Journal of Managed Care & Specialty Pharmacy
https://www.readbyqxmd.com/read/28944315/is-chronic-ahr-activation-by-rapidly-metabolized-ligands-safe-for-the-treatment-of-immune-mediated-diseases
#12
Allison K Ehrlich, Nancy I Kerkvliet
There is a long standing perception that AhR ligands are automatically disqualified from pharmaceutical development due to their induction of Cyp1a1 as well as their potential for causing "dioxin-like" toxicities. However, recent discoveries of new AhR ligands with potential therapeutic applications have been reported, inviting reconsideration of this policy. One area of exploration is focused on the activation of AhR to promote the generation of regulatory T cells, which control the intensity and duration of immune responses...
February 2017: Current Opinion in Toxicology
https://www.readbyqxmd.com/read/28943987/hospital-discharge-what-are-the-problems-information-needs-and-objectives-of-community-pharmacists-a-mixed-method-approach
#13
Lea D Brühwiler, Kurt E Hersberger, Monika Lutters
BACKGROUND: After hospital discharge, community pharmacists are often the first health care professionals the discharged patient encounters. They reconcile and dispense prescribed medicines and provide pharmaceutical care. Compared to the roles of general practitioners, the pharmacists' needs to perform these tasks are not well known. OBJECTIVE: This study aims to a) Identify community pharmacists' current problems and roles at hospital discharge, b) Assess their information needs, specifically the availability and usefulness of information, and c) Gain insight into pharmacists' objectives and ideas for discharge optimisation...
July 2017: Pharmacy Practice
https://www.readbyqxmd.com/read/28943984/factors-affecting-pharmacy-engagement-and-pharmacy-customer-devotion-in-community-pharmacy-a-structural-equation-modeling-approach
#14
Sujin Nitadpakorn, Karen B Farris, Tanattha Kittisopee
BACKGROUND: The concept of customer engagement and devotion has been applied in various service businesses to keep the customers with business However, a limited number of studies were performed to examine the context of customer engagement and devotion in pharmacy business which focus on the impact of customer perceptions about pharmacists, perceived quality of pharmacy structure, medication price strategy on pharmacy engagement and pharmacy customer devotion in a pharmacy providing pharmaceutical care to the customers...
July 2017: Pharmacy Practice
https://www.readbyqxmd.com/read/28943983/the-impact-of-drug-related-problems-on-health-related-quality-of-life-among-hypertensive-patients-in-jordan
#15
Rana Abu Farha, Akram Saleh, Salah Aburuz
BACKGROUND: Hypertension is a major cause of cardiovascular diseases with a high prevalence in Jordan. No previous studies have been carried out to determine the effect of the presence of drug-related problems (DRPs) on the health-related quality of life (HRQOL) among hypertensive patients. OBJECTIVES: The purpose of this study was to identify the influence of different types of DRPs on the HRQOL of hypertensive patients. METHODS: A total of 200 hypertensive patients were recruited in this cross-sectional correlation study that was conducted across the cardiac outpatient clinic at Jordan University Hospital...
July 2017: Pharmacy Practice
https://www.readbyqxmd.com/read/28943593/nationwide-survey-on-informed-consent-and-ethical-review-at-hospitals-conducting-post-marketing-studies-sponsored-by-pharmaceutical-companies
#16
Hisashi Urushihara, Yuka Murakami, Kenji Matsui, Shimon Tashiro
<bibitem lang="en">  Under the Japanese drug regulatory system, post-marketing studies (PMS) must be in compliance with Good Post-marketing Study Practice (GPSP). The GPSP Ordinance lacks standards for the ethical conduct of PMSs; although only post-marketing clinical trials are subject to Good Clinical Practice. <bibitem lang="en">  We conducted a web-based questionnaire survey on the ethical conduct of PMSs in collaboration with the Japanese Society of Hospital Pharmacists and pharmacists belonging to the Society...
September 25, 2017: Yakugaku Zasshi: Journal of the Pharmaceutical Society of Japan
https://www.readbyqxmd.com/read/28943443/advances-in-paper-analytical-methods-for-pharmaceutical-analysis
#17
REVIEW
Niraj Sharma, Toni Barstis, Basant Giri
Paper devices have many advantages over other microfluidic devices. The paper substrate, from cellulose to glass fiber, is an inexpensive substrate that can be readily modified to suit a variety of applications. Milli- to micro-scale patterns can be designed to create a fast, cost-effective device that uses small amounts of reagents and samples. Finally, well-established chemical and biological methods can be adapted to paper to yield a portable device that can be used in resource-limited areas (e.g., field work)...
September 21, 2017: European Journal of Pharmaceutical Sciences
https://www.readbyqxmd.com/read/28943442/the-quest-for-exceptional-drug-solubilization-in-diluted-surfactant-solutions-and-consideration-of-residual-solid-state
#18
Wiebke Saal, Nicole Wyttenbach, Jochem Alsenz, Martin Kuentz
Solubility screening in different surfactant solutions is an important part of pharmaceutical profiling. A particular interest is in low surfactant concentrations that mimic the dilution of an oral dosage form. Despite of intensive previous research on solubilization in micelles, there is only limited data available at low surfactant concentrations and generally missing is a physical state analysis of the residual solid. The present work therefore studied 13 model drugs in 6 different oral surfactant solutions (0...
September 21, 2017: European Journal of Pharmaceutical Sciences
https://www.readbyqxmd.com/read/28943257/immuno-detection-of-cleaved-snap-25-from-differentiated-mouse-embryonic-stem-cells-provides-a-sensitive-assay-for-determination-of-botulinum-a-toxin-and-antitoxin-potency
#19
G Yadirgi, P Stickings, S Rajagopal, Y Liu, D Sesardic
Botulinum toxin type A is a causative agent of human botulism. Due to high toxicity and ease of production it is classified by the Centres for Disease Control and Prevention as a category A bioterrorism agent. The same serotype, BoNT/A, is also the most widely used in pharmaceutical preparations for treatment of a diverse range of neuromuscular disorders. Traditionally, animals are used to confirm the presence and activity of toxin and to establish neutralizing capabilities of countermeasures in toxin neutralization tests...
September 21, 2017: Journal of Immunological Methods
https://www.readbyqxmd.com/read/28943224/the-effect-of-lipophilicity-and-dose-on-the-frequency-of-statin-associated-muscle-symptoms-a-systematic-review-and-meta-analysis
#20
REVIEW
Jordon C Irwin, Saman Khalesi, Andrew S Fenning, Rebecca K Vella
Addressing the factors which lead to the development of statin-associated muscle symptoms (SAMS) is vital for maintaining patient compliance with these pharmaceuticals, and thus improving patient outcomes. This study aimed to clarify the relationship between statin lipophilicity, or dose, and the frequency of adverse muscle symptoms using a systematic review of randomised controlled trials (RCTs). RCTs, including statin monotherapy and placebo groups, which reported data on muscle adverse events were identified through the PubMed and Scopus databases...
September 21, 2017: Pharmacological Research: the Official Journal of the Italian Pharmacological Society
keyword
keyword
4209
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"